BOULDER, Colo., Oct. 29, 2014 /PRNewswire/ -- Array BioPharma Inc. ARRY, -0.78% will report financial results for the first quarter of fiscal 2015 and hold a conference call to discuss those results on Tuesday, November 4, 2014.
Investigator Reinhard Dummer, M.D., presented final results from a 117-patient Phase 2 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, a patient population with an especially poor prognosis.
Chinese search engine Baidu Inc. (ADR) (NASDAQ:BIDU) said Thursday its quarterly profit rose 27 percent as user traffic for its mobile operation surpassed passed its desktop computer-based search business.
Array Biopharma Inc (NASDAQ:ARRY) a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
Array BioPharma Inc. (NASDAQ:ARRY) : Announced the appointment of Victor Sandor, M.D., as Chief Medical Officer. The most frequently observed adverse events included acneiform dermatitis, increased blood creatine phosphokinase and peripheral ...
Array Biopharma Inc (NASDAQ:ARRY) Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain.